Insider Selling: Atara Biotherapeutics (NASDAQ:ATRA) CAO Sells 1,804 Shares of Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CAO Yanina Grant-Huerta sold 1,804 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $13.19, for a total transaction of $23,794.76. Following the completion of the transaction, the chief accounting officer owned 33,454 shares in the company, valued at $441,258.26. The trade was a 5.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Yanina Grant-Huerta also recently made the following trade(s):

• On Monday, November 17th, Yanina Grant-Huerta sold 1,804 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $13.19, for a total transaction of $23,794.76.

Atara Biotherapeutics Stock Up 2.1%

ATRA stock traded up $0.28 during mid-day trading on Wednesday, reaching $13.74. 39,536 shares of the stock traded hands, compared to its average volume of 96,447. The firm has a market capitalization of $99.07 million, a PE ratio of 6.30 and a beta of 0.26. The business has a 50-day moving average of $13.70 and a two-hundred day moving average of $11.05. Atara Biotherapeutics, Inc. has a 52 week low of $5.01 and a 52 week high of $18.70.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.51. Atara Biotherapeutics had a negative return on equity of 41.78% and a net margin of 15.40%.The business had revenue of $3.45 million for the quarter, compared to analyst estimates of $2.74 million. On average, equities research analysts anticipate that Atara Biotherapeutics, Inc. will post -10.39 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ATRA. Staley Capital Advisers Inc. lifted its stake in shares of Atara Biotherapeutics by 60.0% in the first quarter. Staley Capital Advisers Inc. now owns 80,000 shares of the biotechnology company’s stock valued at $475,000 after buying an additional 30,000 shares during the period. EcoR1 Capital LLC increased its stake in Atara Biotherapeutics by 7.7% during the first quarter. EcoR1 Capital LLC now owns 573,183 shares of the biotechnology company’s stock valued at $3,405,000 after acquiring an additional 41,049 shares during the period. Geode Capital Management LLC increased its stake in Atara Biotherapeutics by 2.5% during the second quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company’s stock valued at $464,000 after acquiring an additional 1,457 shares during the period. Marshall Wace LLP acquired a new position in Atara Biotherapeutics in the 2nd quarter valued at approximately $327,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Atara Biotherapeutics in the 2nd quarter worth approximately $31,000. Institutional investors and hedge funds own 70.90% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Atara Biotherapeutics in a research report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.